Clinical Trials
10
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (10 trials with phase data)• Click on a phase to view related trials
Study of Canakinumab in Patients With Myelofibrosis
- Conditions
- Primary MyelofibrosisPost-essential Thrombocythemia MyelofibrosisPV-MFET-MFPost-polycythemia Vera Related Myelofibrosis
- Interventions
- First Posted Date
- 2022-07-21
- Last Posted Date
- 2025-08-19
- Lead Sponsor
- John Mascarenhas
- Target Recruit Count
- 14
- Registration Number
- NCT05467800
- Locations
- 🇺🇸
Mayo Clinic Arizona, Phoenix, Arizona, United States
🇺🇸Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation
- Conditions
- Accelerated/Blast-phase Myeloproliferative NeoplasmChronic-phase MyelofibrosisIDH2 Mutation
- Interventions
- First Posted Date
- 2020-02-24
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- John Mascarenhas
- Target Recruit Count
- 6
- Registration Number
- NCT04281498
- Locations
- 🇺🇸
Mayo Clinic - Arizona, Scottsdale, Arizona, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
MPN-RC 118 AVID200 in Myelofibrosis
- Conditions
- Post-polycythemia Vera MyelofibrosisPost PV MFPrimary MyelofibrosisPost-essential Thrombocythemia MyelofibrosisPost ET MF
- Interventions
- First Posted Date
- 2019-03-29
- Last Posted Date
- 2023-02-10
- Lead Sponsor
- John Mascarenhas
- Target Recruit Count
- 21
- Registration Number
- NCT03895112
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
PD-1 Inhibition in Advanced Myeloproliferative Neoplasms
- Conditions
- Primary MyelofibrosisChronic Phase MyelofibrosisPost-essential Thrombocythemia MyelofibrosisPolycythemia Vera
- Interventions
- First Posted Date
- 2017-02-27
- Last Posted Date
- 2021-06-21
- Lead Sponsor
- John Mascarenhas
- Target Recruit Count
- 10
- Registration Number
- NCT03065400
- Locations
- 🇺🇸
Harvard Medical School Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Montefiore Medical Center Division of Hematology, Department of Oncology, Bronx, New York, United States
🇺🇸Icahn School of Medicine at Mount Sinai, New York, New York, United States
Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia
- Conditions
- Essential ThrombocythemiaPolycythemia Vera
- Interventions
- First Posted Date
- 2015-04-02
- Last Posted Date
- 2019-09-12
- Lead Sponsor
- John Mascarenhas
- Target Recruit Count
- 13
- Registration Number
- NCT02407080
- Locations
- 🇺🇸
Georgetown University Medical Center, Washington, District of Columbia, United States
🇺🇸Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States
- Prev
- 1
- 2
- Next